These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34888514)

  • 41. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.
    Mueller T; Alvarez-Madrazo S; Robertson C; Wu O; Bennie M
    Br J Clin Pharmacol; 2019 Feb; 85(2):422-431. PubMed ID: 30423191
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
    Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK
    Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation.
    Wetmore JB; Roetker NS; Yan H; Reyes JL; Herzog CA
    Stroke; 2020 Aug; 51(8):2364-2373. PubMed ID: 32640949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation.
    Fanning L; Ilomäki J; Bell JS; Dārziņš P
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1427-1436. PubMed ID: 28752255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
    Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
    Monreal-Bosch M; Soulard S; Crespo C; Brand S; Kansal A
    Rev Neurol; 2017 Mar; 64(6):247-256. PubMed ID: 28272725
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.
    Shovlin CL; Millar CM; Droege F; Kjeldsen A; Manfredi G; Suppressa P; Ugolini S; Coote N; Fialla AD; Geisthoff U; Lenato GM; Mager HJ; Pagella F; Post MC; Sabbà C; Sure U; Torring PM; Dupuis-Girod S; Buscarini E;
    Orphanet J Rare Dis; 2019 Aug; 14(1):210. PubMed ID: 31462308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bullous pemphigoid induced by penicillamine in a patient with Wilson disease.
    Popadic S; Skiljevic D; Medenica L
    Am J Clin Dermatol; 2009; 10(1):36-8. PubMed ID: 19170410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation.
    Ujeyl M; Köster I; Wille H; Stammschulte T; Hein R; Harder S; Gundert-Remy U; Bleek J; Ihle P; Schröder H; Schillinger G; Zawinell A; Schubert I
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1317-1325. PubMed ID: 29909576
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
    Wisløff T; Hagen G; Klemp M
    Pharmacoeconomics; 2014 Jun; 32(6):601-12. PubMed ID: 24715603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.
    Lamberts M; Staerk L; Olesen JB; Fosbøl EL; Hansen ML; Harboe L; Lefevre C; Evans D; Gislason GH
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28196815
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants.
    Gilligan AM; Franchino-Elder J; Song X; Wang C; Henriques C; Sainski-Nguyen A; Wilson K; Smith DM; Sander S
    Curr Med Res Opin; 2018 Feb; 34(2):285-295. PubMed ID: 29166800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
    García Rodríguez LA; Martín-Pérez M; Vora P; Roberts L; Balabanova Y; Brobert G; Fatoba S; Suzart-Woischnik K; Schaefer B; Ruigomez A
    BMJ Open; 2019 Sep; 9(9):e031341. PubMed ID: 31542760
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A case of crusted scabies with a bullous pemphigoid-like eruption and nail involvement.
    Nakamura E; Taniguchi H; Ohtaki N
    J Dermatol; 2006 Mar; 33(3):196-201. PubMed ID: 16620226
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
    Simonyi G; Ferenci T; Finta E; Gasparics R; Medvegy M
    Orv Hetil; 2019 Mar; 160(13):509-515. PubMed ID: 30907102
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
    Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
    Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.